2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.
复制标题
2,3-双脱氧肌苷 (ddI) 用于患有获得性免疫缺陷综合征或艾滋病相关综合症的患者。
DOI：
10.1056/nejm199005103221901
复制
发表时间：
1990
期刊：
影响因子：
--
通讯作者：
Valentine,FT
中科院分区：
文献类型：
--
作者：
Lambert,JS;Seidlin,M;Reichman,RC;Plank,CS;Laverty,M;Morse,GD;Knupp,C;McLaren,C;Pettinelli,C;Valentine,FT
2‘，3’-二脱氧肌苷(2‘，3’-dideoxinosine，DDI)是一种嘌呤类似物，在细胞内代谢转换后抑制人类免疫缺陷病毒(HIV)的复制。我们在17名获得性免疫缺陷综合征(AIDS)患者和20名艾滋病相关综合征患者中进行了DDI的I期剂量递增研究。这种药物每天给药两次，剂量范围为每天每公斤体重0.4至66毫克，持续2至44周。DDI的最大口服耐受量估计为每天每公斤12毫克。主要的剂量限制性毒性反应是疼痛的周围神经病变(8例)和胰腺炎(5例)。无症状的血清转氨酶水平升高(13例)和血尿酸水平升高(10例)，但没有剂量相关的血液学毒性。在最大耐受量时，口服后0.6~1h，血浆中DDI的峰值浓度为6.39.6CD4moL/L，平均半衰期为1.5h。在服药后第2、6、10和20周，血清p24抗原水平显著降低，μ细胞数量显著增加。这些变化在所研究的所有剂量水平上都可以看到。34名患者中有25名在6周后临床症状改善或体重增加≥2公斤。我们认为DDI是一种有前途的艾滋病患者或艾滋病相关复合体的治疗药物。其疗效目前正在大规模的对照临床试验中进行评估。(N Engl J Med 1990；322：1333-40)
2′,3′-dideoxyinosine (ddI) is a purine analogue that after intracellular metabolic conversion suppresses the replication of the human immunodeficiency virus (HIV). We conducted a Phase I dose-escalation study of ddI in 17 patients with the acquired immunodeficiency syndrome (AIDS) and 20 patients with AIDS-related complex. The drug was administered twice daily over a dose range of 0.4 to 66 mg per kilogram of body weight per day for 2 to 44 weeks.The maximal tolerated oral dose of ddI was estimated to be 12 mg per kilogram per day. The major dose-limiting toxic effects were a painful peripheral neuropathy (in eight patients) and pancreatitis (in five). Asymptomatic elevations of the serum aminotransferase levels (in 13 patients) and the serum urate level (in 10) were also noted, but there was no dose-related hematologic toxicity. At the maximal tolerated dose, the peak plasma levels of ddI were 6.3 to 9.6 μmol per liter 0.6 to 1 hour after oral administration; the mean plasma half-life was 1.5 hours.The administration of ddI was associated with statistically significant decreases in serum level of p24 antigen and increases in the numbers of CD4 cells at 2, 6, 10, and 20 weeks. These changes were seen at all dose levels studied. Either a clinical improvement or a weight gain of ≥2 kg was observed in 25 of 34 patients at six weeks.We conclude that ddI is a promising therapeutic agent in patients with AIDS or AIDS-related complex. Its efficacy is currently being evaluated in large-scale, controlled clinical trials. (N Engl J Med 1990; 322:1333–40.)
登录
查看更多内容
雾化喷他脒和胰腺炎。
影响因子：
39.2
作者：
C. Hart
通讯作者：
C. Hart
用于检测 HIV 的抗原测试与逆转录酶测定
DOI：
10.1016/s0140-6736(87)91570-4
发表时间：
1987
期刊：
The Lancet
影响因子：
--
作者：
A. Newell;M. Malkovsky;D. Orr;D. Taylor;A. Dalgleish
通讯作者：
A. Dalgleish
人类免疫缺陷病毒 (HIV) 感染中循环 p24 抗原水平和对双脱氧胞苷的反应。
影响因子：
39.2
作者：
T. Merigan;G. Skowron;S. Bozzette;Richman Dd;R. Uttamchandani;M. Fischl;R. Schooley;M. Hirsch;W. Soo;C. Pettinelli;Herbert H. Schaumburg
通讯作者：
Herbert H. Schaumburg
影响因子：
56.9
作者：
LARDER, BA;DARBY, G;RICHMAN, DD
通讯作者：
RICHMAN, DD
艾滋病和晚期艾滋病相关综合症患者的长期齐多夫定治疗
DOI：
10.1001/jama.1989.03430170067030
发表时间：
1989
期刊：
JAMA
影响因子：
--
作者：
M. Fischl;Richman Dd;D. Causey;M. Grieco;Y. Bryson;D. Mildvan;O. Laskin;J. Groopman;P. Volberding;R. Schooley;G. Jackson;D. Durack;J. Andrews;S. Nusinoff;D. Barry
通讯作者：
D. Barry